BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35920264)

  • 21. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.
    Wang Y; Wang L; Tang X; Zhang Y; Zhang N; Zhi B; Niu X
    BMC Med Imaging; 2023 Aug; 23(1):106. PubMed ID: 37582697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
    Li T; Sun L; Li Q; Luo X; Luo M; Xie H; Wang P
    Front Oncol; 2021; 11():825429. PubMed ID: 35155214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram.
    Bjurlin MA; Renson A; Rais-Bahrami S; Truong M; Rosenkrantz AB; Huang R; Taneja SS
    Eur Urol Focus; 2019 Sep; 5(5):815-822. PubMed ID: 29802053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and External Validation of a Prediction Model to Identify Candidates for Prostate Biopsy.
    Wagaskar VG; Lantz A; Sobotka S; Ratnani P; Parekh S; Falagario UG; Li L; Lewis S; Haines Iii K; Punnen S; Wiklund P; Tewari A
    Urol J; 2022 Nov; 19(5):379-385. PubMed ID: 34978065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
    Huang C; Song G; Wang H; Ji G; Li J; Chen Y; Fan Y; Fang D; Xiong G; Xin Z; Zhou L
    Biomed Res Int; 2018; 2018():6368309. PubMed ID: 30276213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of
    Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
    Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
    Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
    BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
    Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
    Front Oncol; 2021; 11():740868. PubMed ID: 34589437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 35. Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI.
    Ma Z; Wang X; Zhang W; Gao K; Wang L; Qian L; Mu J; Zheng Z; Cao X
    World J Surg Oncol; 2023 Mar; 21(1):83. PubMed ID: 36882854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
    Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
    AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
    [No Abstract]   [Full Text] [Related]  

  • 37. Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance.
    Zhong JG; Shi L; Liu J; Cao F; Ma YQ; Zhang Y
    Sci Rep; 2023 Mar; 13(1):4846. PubMed ID: 36964192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging.
    Liang Z; Feng T; Zhou Y; Yang Y; Sun Y; Zhou Z; Yan W; Cao F
    Am J Cancer Res; 2024; 14(1):73-85. PubMed ID: 38323293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The diagnostic value of version 2.1 prostate imaging reporting and data system for prostate transitional zone lesions].
    Yang S; Zhang CY; Zhang YY; Tan SX; Wei CG; Shen XH; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3609-3613. PubMed ID: 33333685
    [No Abstract]   [Full Text] [Related]  

  • 40. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
    Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.